Surveillance of HIV drug resistance transmission in Iran: Experience gained from a pilot study

Archives of Virology

Volumn 155, Issue 3, 2010, Pages 329-334

  Mousavi, Seyed Mohsen ^a,b   Hamkar, Rasool ^b   Gouya, Mohammad Mehdi ^c   Safaie, Afshin ^c   Zahraei, Seyed Mohsen ^c   Yazdani, Zinab ^c   Namini, Somayeh Asbaghi ^b   Bertagnolio, Silvia ^d   Sutherland, Donald ^d   Sandstrom, Paul ^e   Brooks, James ^e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CLASSIFICATION; DISEASE TRANSMISSION; DNA SEQUENCE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRAN; ISOLATION AND PURIFICATION; MALE; MISSENSE MUTATION; PHYLOGENY; PILOT STUDY; SEQUENCE HOMOLOGY; VIROLOGY;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IRAN; MALE; MUTATION, MISSENSE; PHYLOGENY; PILOT PROJECTS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; YOUNG ADULT;

EID: 77949911704     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-009-0583-6     Document Type: Article

References (22)

1. (2006) HIV/AIDS national report of I. R. Iran. Ministry of Health, Center for Disease Control and Prevention, HIV/AIDS Office. (Persian).
2. (2005) Protocol for evaluation of transmitted HIV drug resistance using specimens from HIV sentinel serosurveys in resource-limited settings (draft). WHO HIV ResNet.
3. Adje C, Cheingsong R et al (2001) High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 26(5): 501-506.
4. Bennett DE, Myatt M et al (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13(Suppl 2): 25-36.
5. Bertagnolio S, Soto-Ramirez L et al (2007) HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12(1): 107-113.
6. Buckton AJ, Bissett SL et al (2008) Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother 62(6): 1191-1198.
7. Day C, Nassirimanesh B et al (2006) Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J 3: 2.
8. Duwe S, Brunn M et al (2001) Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26(3): 266-273.
9. Garrido C, Zahonero N et al (2008) Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 61(3): 694-698.
10. Harris ME, Serwadda D et al (2002) Among 46 near full length HIV type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 18(17): 1281-1290.
11. Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16: 111-120.
12. Larijani B, Zahedi F et al (2005) Medical ethics in the Islamic Republic of Iran. East Mediterr Health J 11(5-6): 1061-1072.
13. McNulty A, Jennings C et al (2007) Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45(2): 517-521.
14. Naderi HR, Tagliamonte M et al (2006) Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. Infect Agent Cancer 1: 4.
15. Razzaghi EM, Movaghar AR et al (2006) Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 3: 12.
16. Richman DD, Morton SC et al (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18(10): 1393-1401.
17. Sanders-Buell E, Saad MD et al (2007) A nascent HIV type 1 epidemic among injecting drug users in Kabul, Afghanistan is dominated by complex AD recombinant strain, CRF35_AD. AIDS Res Hum Retroviruses 23(6): 834-839.
18. Sarrami-Forooshani R, Das SR et al (2006) Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol 78(7): 853-863.
19. Tagliamonte M, Naderi HR et al (2007) HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran. AIDS Res Hum Retroviruses 23(12): 1569-1574.
20. Vazirian M, Nassirimanesh B et al (2005) Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J 2: 19.
21. Yerly S, Vora S et al (2001) Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 15(17): 2287-2292.
22. Zamani S, Kihara M et al (2006) High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr 42(3): 342-346.